Overview

* Shattuck Labs ( STTK ) Q3 net loss narrows to $10.1 mln from $16.6 mln year-over-year

* Company closed $103 mln private placement to fund SL-325 development

* R&D expenses fell to $7.6 mln from $16.3 mln year-over-year

Outlook

* Shattuck expects cash reserves to fund operations into 2029

Result Drivers

* PRIVATE PLACEMENT - Closed $103 mln private placement to advance SL-325 into Phase 2 trials

* R&D EXPENSES - R&D expenses fell to $7.6 mln from $16.3 mln year-over-year, reflecting focused investment in SL-325

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$10.06

Income mln

Q3 Basic -$0.14

EPS

Q3 -$10.72

Income mln

From

Operatio

ns

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Shattuck Labs Inc ( STTK ) is $2.00, about 2% below its November 5 closing price of $2.04

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)